This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesDisease AwarenessDisease AwarenessAspergillosisOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseINSPIRE To: Change the Course Season 2The global threat of carbapenemase-producing enterobacterales (CPE)CPE Epidemiology CPE Factsheet London AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Online Learning
INSPIRE To: Change the Course

Old moulds, new problems - Fungal infections in the ICU

Dr Neil Stone | Consultant in Infectious Diseases, Microbiology & Virology | University College London Hospitals NHS Foundation Trust 

In this 3-part series, Dr Neil Stone:

  • Discusses Candidaemia infections in the ICU and why knowing the risk factors for and symptoms is so important.
  • Explores the importance of judicious use of antifungal therapies, and deep-dives into the currently available options and considerations for their use.

At the end of the course, you will be able to download a certificate of completion.

Dr Neil Stone is a Consultant in Infectious Diseases and Microbiology at the Hospital for Tropical Diseases/University College London Hospitals.

 

Candidaemia in the ICU

Dr Neil Stone explores Candidaemia and why they are so pertinent to patients in the ICU. This video discusses the risk factors for Candidaemia infections and aims to help you recognise signs of this problematic infection.

Learning objectives & questions to consider
Learning Objectives:
  • Be aware of the high mortality rates associated with various fungal infections
  • Recognise the risk factors and signs for Candidaemia in the ICU patients
  • Understand the challenges in diagnosing Candidaemia infections based on current tests 
Questions to consider:
  • When would you suspect Candidaemia in the ICU?
  • What are the limitations of current tests for Candidaemia?

 

The importance of antifungal stewardship

Dr Neil Stone discusses judicious use of antifungals and the three key reasons why this is crucial, now more than ever.

Learning objectives & questions to considerLearning objectives:
  • Understand the reasons and consequences of current overuse of antifungal therapies
Questions to consider:
  • What are potential explanations for current overuse of antifungal therapies?
  • What are the three key reasons why judicious use of antifungals is important?
  • What are the dangers associated with the emergence of multidrug-resistant 
Candida auris?

Current antifungal therapies

Dr Neil Stone explores the current antifungal landscape and key considerations for the use of these therapies.

Learning objectives & questions to considerLearning objectives:
  • Be aware of current antifungal therapies and their applications, strengths and limitations
Question to consider:
  • What are the three main classes of antifungal therapies and the key considerations for their use?

Certificate Download

Download a certificate to demonstrate your completion of the Neil Stone video Series: Old moulds, new problems – Fungal infections on the ICU 

DownloadLoading
Learn more - Lisa Nwanko 

Click here to learn more about the management of invasive aspergillosis (IA) in an ICU setting. 

Go to the next moduleLoading

CRESEMBA® (isavuconazole) is indicated in adults for the treatment of Invasive Aspergillosis and also for the treatment of Mucormycosis in patients for whom amphotericin B is inappropriate.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Learn more
Loading

ICU, intensive care unit.

Prescribing Information:

Click here for Prescribing Information for CRESEMBA® (isavuconazole) and Vfend (voriconazole)

PP-CRB-GBR-2501. June 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​